If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humalog Summary of Product Characteristics (SmPC)
The pharmacokinetics of Humalog Mix are representative of the individual pharmacokinetic property of the two components
The
pharmacokinetics of insulin lispro reflect a compound that is rapidly
absorbed and achieves peak blood levels 30 to 70 minutes following
subcutaneous injection. The pharmacokinetics of insulin lispro
protamine suspension are consistent with those of an intermediate
acting insulin such as NPH. The pharmacokinetics of Humalog Mix25 and
Humalog Mix50 are representative of the individual pharmacokinetic
properties of the two components. When considering the clinical
relevance of these kinetics, it is more appropriate to examine the
glucose utilisation curves.
Insulin
lispro maintains more rapid absorption when compared to soluble human
insulin in patients with renal impairment. In patients with type 2
diabetes over a wide range of renal function the pharmacokinetic
differences between insulin lispro and soluble human insulin were
generally maintained and shown to be independent of renal function.
Insulin lispro maintains more rapid absorption and elimination when
compared to soluble human insulin in patients with hepatic
impairment.
Reference
Humalog
Mix 25 [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.
Humalog
Mix 50 [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.
Date of Last Review:January 10, 2019
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com